| UHC Commercial Medical & Drug | Ketalar® (Ketamine) and Spravato® (Esketamine) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Light and Laser Therapy - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Liposuction for Lipedema - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Luxturna® (Voretigene Neparvovec-Rzyl) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Manipulative Therapy - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Maximum Dosage and Frequency - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Mechanical Stretching Devices - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Minimally Invasive Procedures for Gastric and Esophageal Diseases - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions - Commercial and Individual Exchange Medical Policy | 2026-01-01 |